Expert perspectives on biosimilar monoclonal antibodies in breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s10549-014-2879-9.pdf
Reference39 articles.
1. Slamon DJ, Leyland-Jones B, Shak S et al (2009) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792
2. Perez EA, Romond EH, Suman VJ et al (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2–positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366–3373
3. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, Herceptin Adjuvant (HERA) Trial Study Team et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomized controlled trial. Lancet 382:1021–1028
4. Revers L, Furczon E (2010) An introduction to biologics and biosimilars. Part II: Subsequent entry biologics: biosame or biodifferent? Can Pharm J 143:184–191
5. Weise M, Bielsky MC, De Smet K et al (2011) Biosimilars—why terminology matters. Nat Biotechnol 29:691–693
Cited by 44 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A Randomized, Single‐dose, Phase I Clinical Comparison of a Trastuzumab Biosimilar With a Reference Trastuzumab Formulation in Healthy Chinese Male Volunteers;Clinical Pharmacology in Drug Development;2022-11
2. Therapeutic applications of biosimilar monoclonal antibodies: Systematic review of the efficacy, safety, and immunogenicity in autoimmune disorders;International Immunopharmacology;2021-12
3. Relationship between innovative and biosimilar trastuzumab used in the treatment of breast cancer: cross-sectional study of financial impact;Journal of Cancer Prevention & Current Research;2021-07-29
4. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars;Future Oncology;2021-07
5. Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations;Oncology and Therapy;2021-01-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3